New Study Shows Promising Results in Mouse Models, Highlighting Potential for Long-Term Human Treatments
Recent research presented at the Federation of European Neuroscience Societies (FENS) Forum 2024 has found that cannabidiol (CBD) and metformin can alleviate behavioral difficulties in mouse models of Fragile X and Phelan-McDermid syndromes, both of which are linked to autism spectrum disorder (ASD). The research conducted at McGill University, showed that these treatments improved speech, social interactions, and reduced repetitive behaviors in the mice. The study demonstrated that metformin corrected biochemical differences in the brain, prevented impaired speech, and reduced repetitive behaviors, while CBD normalized social and repetitive behaviors in young mice. These improvements persisted into the mice’s adulthood with minimal side effects, making these drugs potentially viable for long-term use. Ongoing clinical trials aim to confirm these findings in humans, which could lead to new, effective treatments for individuals with ASD and related conditions, offering hope for improved quality of life and developmental outcomes. The researchers are also investigating the broader applicability of these drugs for other autism spectrum disorder-related conditions.
